Saposin C pharmaceutical compositions and methods of treating cancer
First Claim
Patent Images
1. A composition comprising:
- a polypeptide comprising the amino acid sequence of SEQ ID NO;
1 with zero to four amino acid insertions, substitutions, or deletions;
a phosphatidylserine lipid;
a buffer at pH 5.0 to 8.0;
trehalose at 1.5 to 9 percent w/w;
t-butyl alcohol at 0 to 35 percent; and
water,wherein the polypeptide is at a concentration of 0.4 to 5.0 mg/ml, and the molar ratio of the phosphatidylserine lipid to the polypeptide is in the range of 8;
1 to 20;
1.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are pharmaceutical compositions containing saposin C and phosphatidylserine that are useful for treating various cancers.
14 Citations
41 Claims
-
1. A composition comprising:
-
a polypeptide comprising the amino acid sequence of SEQ ID NO;
1 with zero to four amino acid insertions, substitutions, or deletions;a phosphatidylserine lipid; a buffer at pH 5.0 to 8.0; trehalose at 1.5 to 9 percent w/w; t-butyl alcohol at 0 to 35 percent; and water, wherein the polypeptide is at a concentration of 0.4 to 5.0 mg/ml, and the molar ratio of the phosphatidylserine lipid to the polypeptide is in the range of 8;
1 to 20;
1.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
the phosphatidylserine lipid is DOPS and is at a concentration of 2.0 to 2.8 mg/ml; the buffer is Tris at a concentration of 23 to 27 mM; the trehalose is at a concentration of 4 to 6 percent w/w; the pH of the composition is in the range of pH 6.8 to 7.6; and the composition further comprises t-butyl alcohol at a concentration of about 15 to 25 percent w/w.
-
-
11. A composition in solid form comprising:
-
a polypeptide comprising the amino acid sequence of SEQ ID NO;
1 with zero to four amino acid insertions, substitutions, or deletions;a phosphatidylserine lipid; a buffer; and trehalose at 75 to 90 percent w/w, wherein the polypeptide is at a concentration of 3.2 to 4.4 percent w/w, and the molar ratio of phosphatidylserine lipid to polypeptide is in the range of 8;
1 to 20;
1.- View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 41)
the phosphatidylserine lipid is DOPS and is at a concentration of 3.4 to 4.8 percent w/w; the buffer is Tris and is at a concentration of 6.0 to 7.2 percent w/w; the trehalose is at a concentration of 81 to 87.3 percent w/w; and the composition further comprises t-butyl alcohol at a concentration of less than 3 percent w/w.
-
-
41. A method of treating cancer in a human patient, the method comprising reconstituting the composition of claim 11 in water or saline to produce a reconstituted composition, and intravenously administering a dose of the reconstituted composition to the patient.
-
22. A pharmaceutical composition comprising:
-
a polypeptide comprising the amino acid sequence of SEQ ID NO;
1 with zero to four amino acid insertions, substitutions, or deletions;a phosphatidylserine lipid; a buffer at pH 5.0 to 8; trehalose at 1.5 to 9 percent w/v; and water, wherein the polypeptide is at a concentration of 0.4 to 5 mg/ml, and the molar ratio of phosphatidylserine lipid to polypeptide is in the range of 8;
1 to 20;
1.- View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)
the phosphatidylserine lipid is DOPS and is at a concentration of 2.0 to 2.8 mg/ml; the buffer is Tris and is at a concentration of 23 to 27 mM; the trehalose is at a concentration of 4 to 6 percent w/w; the pH of the composition is in the range of pH 6.8 to 7.6; and the composition further comprises t-butyl alcohol in an amount less than 0.5 percent w/w.
-
-
33. A method of treating cancer in a human patient, the method comprising administering the composition of claim 22 to the patient.
-
34. The method of claim 33, wherein the patient has a solid tumor.
-
35. The method of claim 34, wherein the patient has a glioma or ependymoma.
-
36. The method of claim 34, wherein the patient has a gastrointestinal cancer.
-
37. The method of claim 33, wherein the composition is delivered intravenously in a dose ranging from 0.4 mg/kg to 7 mg/kg SapC, and the ratio of SapC to DOPS in the composition is in the range of 1:
- 8 to 1;
20.
- 8 to 1;
-
38. The method of claim 33, wherein the composition is delivered intravenously in a dose of 2.3-2.5 mg/kg SapC, and the ratio of SapC to DOPS in the composition is in the range of 1:
- 11 to 1;
13.
- 11 to 1;
-
39. The method of claim 37, wherein the composition is administered repeatedly to the patient over at least two cycles, as follows:
-
Cycle 1; week 1;
one dose on each of days 1-5;week 2;
three doses every other day;weeks 3 and 4;
one dose each week (every 7 (+/−
3) days);Cycle 2;
one dose during week 5.
-
-
40. The method of claim 39, further comprising at least one subsequent cycle, wherein the at least one subsequent cycle comprises:
- one dose 28 (+/−
3) days after the most recent prior dose.
- one dose 28 (+/−
Specification